文献速递瓣膜外科

Perceval免缝合主动脉瓣真实世界注册研究的临床与血流动力学结局

Clinical and hemodynamic outcomes of the Perceval sutureless aortic valve from a real-world registry.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2023-01-01

基于SURE-主动脉瓣置换国际前瞻性注册研究,2011至2021年间55家机构共1652例患者置入Perceval免缝合瓣膜,平均年龄75.3±7.0岁,EuroSCORE II 4.1±6.3。结果显示30天内瓣膜相关再干预率0.3%和0.7%,永久起搏器植入5.7%,平均压差由术前45.8±16.5 mmHg降至出院时13.3±5.2 mmHg并在随访中保持稳定。作者认为Perceval是传统外科主动脉瓣置换安全有效的替代选择。

要点

  • 30天内瓣膜相关再干预率为0.3%和0.7%,短暂性脑缺血发作0.4%,致残性卒中0.4%,非致残性卒中0.7%。
  • 永久起搏器植入率5.7%,人工瓣膜内反流≥2级0.2%,瓣周漏≥2级0.1%。
  • 平均压差从术前45.8±16.5 mmHg降至出院时13.3±5.2 mmHg,随访期间保持稳定。

核心结论

  • Perceval是传统外科主动脉瓣置换安全有效的替代选择,在中期的随访中提供了良好的临床和血流动力学结果。

研究设计与样本

  • SURE-主动脉瓣置换国际前瞻性注册研究,2011至2021年间55家机构共纳入1652例接受Perceval瓣膜的患者,分析术后、随访和超声心动图结局。

主要发现

  • 患者平均年龄75.3±7.0岁,女性占53.9%,平均EuroSCORE II为4.1±6.3,45.3%采用微创入路,35.9%合并其他手术。
  • 30天内瓣膜相关再干预率为0.3%和0.7%,短暂性脑缺血发作0.4%,致残性卒中0.4%,非致残性卒中0.7%,永久起搏器植入5.7%。
  • 人工瓣膜内反流≥2级占0.2%,瓣周漏≥2级仅占0.1%。
  • 最长随访8年,心血管死亡1.9%,瓣膜相关再干预0.8%;10例结构性瓣膜衰败(置入后平均5.6±1.4年,范围2.6-7.3年),其中9例经导管瓣中瓣置入,1例取出瓣膜。
  • 平均压差从术前45.8±16.5 mmHg降至出院时13.3±5.2 mmHg,随访期间保持稳定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Perceval sutureless valve has been in clinical use for >15 years. The aim of this study is to report the real-word clinical and haemodynamic performance from the SURE-aortic valve replacement international prospective registry in patients who underwent aortic valve replacement with Perceval valve. METHODS: From 2011 to 2021, patients from 55 institutions received a Perceval valve. Postoperative, follow-up, and echocardiographic outcomes were analysed. RESULTS: A total of 1652 patients were included; mean age was 75.3 ± 7.0 years (53.9% female); mean EuroSCORE II was 4.1 ± 6.3. Minimally invasive approach was performed in 45.3% of patients; concomitant procedures were done in 35.9% of cases. Within 30 days, 0.3 and 0.7% valve-related reinterventions were reported. Transient ischaemic attack, disabling and non-disabling strokes were limited (0.4%, 0.4% and 0.7%, respectively). Pacemaker implant was required in 5.7% of patients. Intra-prosthetic regurgitation ≥2 was present in 0.2% of cases, while paravalvular leak ≥2 in only 0.1%. At a maximum follow-up of 8 years, 1.9% of cardiovascular deaths and 0.8% of valve-related reintervention occurred. Among the 10 cases of structural valve deterioration (mean 5.6 ± 1.4 years after implant; range: 2.6-7.3 years), 9 were treated with a transcatheter vale-in-valve implantation and 1 with explant. Mean pressure gradient decreased from 45.8 ± 16.5 mmHg preoperatively to 13.3 ± 5.2 mmHg at discharge and remained stable during follow-up. CONCLUSIONS: This experience represents the largest prospective real-world cohort of patients treated with Perceval showing that Perceval is a safe and effective alternative to conventional surgical aortic valve replacement, providing favourable clinical and haemodynamic results also at mid-term follow-up.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Concistré G, Baghai M, Santarpino G, et al. Clinical and hemodynamic outcomes of the Perceval sutureless aortic valve from a real-world registry. Interdiscip Cardiovasc Thorac Surg. 2023. PMID: 37307090. doi:10.1093/icvts/ivad103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。